Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
NCT ID | NCT03763149 |
Title | A Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-cluster Differentiation Antigen 47 (CD47) Monoclonal Antibody Injection (IBI188) in Patients With Advanced Malignant Tumors and Lymphomas |
Recruitment | Completed |
Gender | both |
Phase | Phase I |
Variant Requirements | No |
Sponsors | Innovent Biologics (Suzhou) Co. Ltd. |
Indications | |
Therapies | |
Age Groups: | adult | senior |
Covered Countries | USA |